---
document_datetime: 2023-09-21 20:12:18
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vepacel-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: vepacel-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.2044086
conversion_datetime: 2025-12-20 07:15:20.505427
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on Issued   | Commission Decision 2 / Product Information affected 3   | Summary                           |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|----------------------------------------------------------|-----------------------------------|
| T/0019               | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 23/11/2018 11/01/2019                      | SmPC, Labelling and PL                                   |                                   |
| PSUSA/2282/ 201708   | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (whole virion, vero cell derived, inactivated), prepandemic influenza vaccine (H5N1) (whole virion, vero cell derived, inactivated) 12/04/2018 product | amended on n/a                             |                                                          | PRAC Recommendation - maintenance |

Telephone

+44 (0)20 3660 6000

Facsimile

+44 (0)20 3660 5520

<!-- image -->

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom An agency of the European Union Send a question via our website www.ema.europa.eu/contact Vepacel Procedural steps taken and scientific information after the authorisation 1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures. 2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). edicinal product no longer auth

<div style=\"page-break-after: always\"></div>

| T/0017             | Transfer of Marketing Authorisation                                                                                                                                                                                           | 10/03/2017   | 03/04/2017   | SmPC, Labelling and PL        |                                                                                                                                                                                                                                                                       |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2282/ 201608 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (whole virion, vero cell derived, inactivated), prepandemic influenza vaccine (H5N1) (whole virion, vero cell derived, inactivated)           | 09/03/2017   | n/a          |                               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| R/0015             | Renewal of the marketing authorisation.                                                                                                                                                                                       | 10/11/2016   | 04/01/2017   | SmPC, Labelling and PL longer | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Vepacel in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/2282/ 201508 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (whole virion, vero cell derived, inactivated), prepandemic influenza vaccine (H5N1) (whole virion, vero cell derived, inactivated) product   | 17/03/2016   | n/a no       |                               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| T/0013             | Transfer of Marketing Authorisation                                                                                                                                                                                           | 05/11/2015   | 30/11/2015   | SmPC, Labelling and PL        |                                                                                                                                                                                                                                                                       |
| IAIN/0012/G        | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV | 02/06/2015   | 30/11/2015   | SmPC, Labelling and PL        |                                                                                                                                                                                                                                                                       |

edicinal product no longer authorise

<div style=\"page-break-after: always\"></div>

|                    | (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |               |                       |                                   |                                                                                                            |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-----------------------|-----------------------------------|------------------------------------------------------------------------------------------------------------|
| PSUSA/2282/ 201408 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (whole virion, vero cell derived, inactivated), prepandemic influenza vaccine (H5N1) (whole virion, vero cell derived, inactivated)                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/03/2015    | n/a                   |                                   | PRAC Recommendation - maintenance                                                                          |
| PSUV/0010          | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 09/10/2014    | n/a                   |                                   | PRAC Recommendation - maintenance                                                                          |
| PSUV/0009          | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/04/2014    | n/a                   |                                   | PRAC Recommendation - maintenance                                                                          |
| II/0007            | Extension of Indication to include the paediatric population for Vepacel. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC were updated in order to include new safety and efficacy information. The Labelling and Package Leaflet are updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is being brought in line with the latest QRD template version 9, the SmPC guideline and the Core SmPC for pandemic vaccines. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one product | 24/10/2013 no | 25/11/2013 25/11/2013 | SmPC, Annex Labelling and PL SmPC | II, Please refer to the scientific discussion of the Assessment Report Vepacel-H-2089-II-07-VAR-en. longer |
| IB/0008            | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 13/08/2013    |                       |                                   |                                                                                                            |

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0006   | Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product   | 27/06/2013   | n/a                                  |          |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------------------------|----------|
| IB/0005   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                        | 08/02/2013   | n/a longer                           |          |
| II/0002   | To add an additional primary container for the finished product. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Type of container - Sterile medicinal products and biological/immunological medicinal product                                                                                                                                                                                               | 19/07/2012   | 04/10/2012 SmPC, Labelling and PL no | products |
| IG/0214   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                             | 14/09/2012   | n/a                                  |          |
| IB/0001   | B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a                                                                                                                                                                                                                                                                                                                              | 08/05/2012   | n/a                                  |          |

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | biological/immunological AS is increased/decreased without process change (e.g. duplication of line)               |     |
|-----------|--------------------------------------------------------------------------------------------------------------------|-----|
| IAIN/0003 | C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database | n/a |

<!-- image -->